

Andrea L Cox

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6860388/publications.pdf>

Version: 2024-02-01

126
papers

9,925
citations

57719

44
h-index

37183

96
g-index

145
all docs

145
docs citations

145
times ranked

9893
citing authors

#	ARTICLE	IF	CITATIONS
1	Differential Cytokine Signatures of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Influenza Infection Highlight Key Differences in Pathobiology. <i>Clinical Infectious Diseases</i> , 2022, 74, 254-262.	2.9	28
2	The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV). <i>Clinical Infectious Diseases</i> , 2022, 74, 1268-1270.	2.9	118
3	A third dose of SARS-CoV-2 vaccine increases neutralizing antibodies against variants of concern in solid organ transplant recipients. <i>American Journal of Transplantation</i> , 2022, 22, 1253-1260.	2.6	73
4	B cell overexpression of FCRL5 and PD-1 is associated with low antibody titers in HCV infection. <i>PLoS Pathogens</i> , 2022, 18, e1010179.	2.1	6
5	Higher Proinflammatory Cytokines Are Associated With Increased Antibody Titer After a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients. <i>Transplantation</i> , 2022, 106, 835-841.	0.5	15
6	Trans-ancestral fine-mapping of MHC reveals key amino acids associated with spontaneous clearance of hepatitis C in HLA-DQ1 ² . <i>American Journal of Human Genetics</i> , 2022, 109, 299-310.	2.6	6
7	Differentiation of Individuals Previously Infected with and Vaccinated for SARS-CoV-2 in an Inner-City Emergency Department. <i>Journal of Clinical Microbiology</i> , 2022, 60, jcm0239021.	1.8	5
8	Adaptive immune responses in vaccinated patients with symptomatic SARS-CoV-2 Alpha infection. <i>JCI Insight</i> , 2022, 7, .	2.3	12
9	IgM anti-ACE2 autoantibodies in severe COVID-19 activate complement and perturb vascular endothelial function. <i>JCI Insight</i> , 2022, 7, .	2.3	23
10	Continued Virus-Specific Antibody-Secreting Cell Production, Avidity Maturation and B Cell Evolution in Patients Hospitalized with COVID-19. <i>Viral Immunology</i> , 2022, 35, 259-272.	0.6	4
11	A Fourth Dose of COVID-19 Vaccine Does Not Induce Neutralization of the Omicron Variant Among Solid Organ Transplant Recipients With Suboptimal Vaccine Response. <i>Transplantation</i> , 2022, 106, 1440-1444.	0.5	49
12	SARS-CoV-2-specific immune responses in boosted vaccine recipients with breakthrough infections during the Omicron variant surge. <i>JCI Insight</i> , 2022, 7, .	2.3	15
13	Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	5
14	SARS-CoV-2 vaccination diversifies the CD4+ spike-reactive T cell repertoire in patients with prior SARS-CoV-2 infection. <i>EBioMedicine</i> , 2022, 80, 104048.	2.7	12
15	Cross-reactive antibodies facilitate innate sensing of dengue and Zika viruses. <i>JCI Insight</i> , 2022, 7, .	2.3	2
16	Repeated exposure to heterologous hepatitis C viruses associates with enhanced neutralizing antibody breadth and potency. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	5
17	Markers of endothelial cell activation are associated with the severity of pulmonary disease in COVID-19. <i>PLoS ONE</i> , 2022, 17, e0268296.	1.1	12
18	A Multiancestry Sex-Stratified Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus. <i>Journal of Infectious Diseases</i> , 2021, 223, 2090-2098.	1.9	5

#	ARTICLE	IF	CITATIONS
19	Randomized Trial of a Vaccine Regimen to Prevent Chronic HCV Infection. <i>New England Journal of Medicine</i> , 2021, 384, 541-549.	13.9	101
20	Metabolic programs define dysfunctional immune responses in severe COVID-19 patients. <i>Cell Reports</i> , 2021, 34, 108863.	2.9	92
21	People with HIV-1 Demonstrate Type 1 Interferon Refractoriness Associated with Upregulated USP18. <i>Journal of Virology</i> , 2021, 95, .	1.5	4
22	Functional characterization of CD4+ T cell receptors crossreactive for SARS-CoV-2 and endemic coronaviruses. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	72
23	Cell-free DNA maps COVID-19 tissue injury and risk of death and can cause tissue injury. <i>JCI Insight</i> , 2021, 6, .	2.3	86
24	Delayed Rise of Oral Fluid Antibodies, Elevated BMI, and Absence of Early Fever Correlate With Longer Time to SARS-CoV-2 RNA Clearance in a Longitudinally Sampled Cohort of COVID-19 Outpatients. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab195.	0.4	13
25	Durable SARS-CoV-2 B cell immunity after mild or severe disease. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	76
26	Distinct Cytokine and Chemokine Dysregulation in Hospitalized Children With Acute Coronavirus Disease 2019 and Multisystem Inflammatory Syndrome With Similar Levels of Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 Shedding. <i>Journal of Infectious Diseases</i> , 2021, 224, 606-615.	1.9	30
27	Interleukin-18 and tumor necrosis factor- α are elevated in solid organ transplant recipients with possible cytomegalovirus end-organ disease. <i>Transplant Infectious Disease</i> , 2021, 23, e13682.	0.7	4
28	The NIH Lipo-COVID Study: A Pilot NMR Investigation of Lipoprotein Subfractions and Other Metabolites in Patients with Severe COVID-19. <i>Biomedicines</i> , 2021, 9, 1090.	1.4	22
29	Controlled Human Infection Model "Fast Track to HCV Vaccine?". <i>New England Journal of Medicine</i> , 2021, 385, 1235-1240.	13.9	22
30	High-value laboratory testing for hospitalized COVID-19 patients: a review. <i>Future Virology</i> , 2021, 16, 691-705.	0.9	11
31	The Clinical Course of COVID-19 in the Outpatient Setting: A Prospective Cohort Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab007.	0.4	55
32	Plasma virome and the risk of blood-borne infection in persons with substance use disorder. <i>Nature Communications</i> , 2021, 12, 6909.	5.8	8
33	Sex Discrepancies in the Protective Effect of Opioid Agonist Therapy on Incident Hepatitis C Infection. <i>Clinical Infectious Diseases</i> , 2020, 70, 123-131.	2.9	7
34	Challenges and Promise of a Hepatitis C Virus Vaccine. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a036947.	2.9	30
35	Progress towards elimination goals for viral hepatitis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 533-542.	8.2	118
36	Multi-ancestry fine mapping of interferon lambda and the outcome of acute hepatitis C virus infection. <i>Genes and Immunity</i> , 2020, 21, 348-359.	2.2	5

#	ARTICLE	IF	CITATIONS
37	Antibody avidity-based approach to estimate population-level incidence of hepatitis C. <i>Journal of Hepatology</i> , 2020, 73, 294-302.	1.8	3
38	Evolving trends in the prevalence of hepatitis C virus antibody positivity among HIV-infected men in a community-based primary care setting. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1202-1213.	1.0	1
39	Herpes simplex virus type 1 inflammasome activation in proinflammatory human macrophages is dependent on NLRP3, ASC, and caspase-1. <i>PLoS ONE</i> , 2020, 15, e0229570.	1.1	27
40	Ethical and Practical Issues Associated With the Possibility of Using Controlled Human Infection Trials in Developing a Hepatitis C Virus Vaccine. <i>Clinical Infectious Diseases</i> , 2020, 71, 2986-2990.	2.9	7
41	Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2. <i>Journal of Virology</i> , 2019, 93, .	1.5	37
42	Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus. <i>Gastroenterology</i> , 2019, 156, 1496-1507.e7.	0.6	32
43	Genomic characterization of hepatitis C virus transmitted founder variants with deep sequencing. <i>Infection, Genetics and Evolution</i> , 2019, 71, 36-41.	1.0	14
44	Inconsistent temporal patterns of genetic variation of HCV among high-risk subjects may impact inference of transmission networks. <i>Infection, Genetics and Evolution</i> , 2019, 71, 1-6.	1.0	2
45	Trends in hepatitis C treatment initiation among HIV/hepatitis C virus-coinfected men engaged in primary care in a multisite community health centre in Maryland: a retrospective cohort study. <i>BMJ Open</i> , 2019, 9, e027411.	0.8	6
46	Approaches, Progress, and Challenges to Hepatitis C Vaccine Development. <i>Gastroenterology</i> , 2019, 156, 418-430.	0.6	162
47	Genomic variability of within-host hepatitis C variants in acute infection. <i>Journal of Viral Hepatitis</i> , 2019, 26, 476-484.	1.0	6
48	Plasma deconvolution identifies broadly neutralizing antibodies associated with hepatitis C virus clearance. <i>Journal of Clinical Investigation</i> , 2019, 129, 4786-4796.	3.9	33
49	The Effect of Female Sex on Hepatitis C Incidence Among People Who Inject Drugs: Results From the International Multicohort InC3 Collaborative. <i>Clinical Infectious Diseases</i> , 2018, 66, 20-28.	2.9	21
50	Complex patterns of Hepatitis-C virus longitudinal clustering in a high-risk population. <i>Infection, Genetics and Evolution</i> , 2018, 58, 77-82.	1.0	12
51	Opioids, Hepatitis C Virus Infection, and the Missing Vaccine. <i>American Journal of Public Health</i> , 2018, 108, 156-157.	1.5	8
52	Can Broadly Neutralizing Monoclonal Antibodies Lead to a Hepatitis C Virus Vaccine?. <i>Trends in Microbiology</i> , 2018, 26, 854-864.	3.5	39
53	Interventional Radiation Oncology (IRO): Transition of a magnetic resonance simulator to a brachytherapy suite. <i>Brachytherapy</i> , 2018, 17, 587-596.	0.2	7
54	Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection. <i>Cell Host and Microbe</i> , 2018, 24, 717-730.e5.	5.1	78

#	ARTICLE	IF	CITATIONS
55	Medical school research ranking is associated with gender inequality in MSTP application rates. BMC Medical Education, 2018, 18, 187.	1.0	15
56	Balancing Research, Teaching, Clinical Care, and Family: Can Physician-Scientists Have it All?. Journal of Infectious Diseases, 2018, 218, S32-S35.	1.9	8
57	Systemic Elevation of Proinflammatory Interleukin 18 in HIV/HCV Coinfection versus HIV or HCV Mono-infection. Clinical Infectious Diseases, 2017, 64, ciw771.	2.9	17
58	Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection. Infection, Genetics and Evolution, 2017, 49, 88-96.	1.0	8
59	Factors Associated With the Control of Viral Replication and Virologic Breakthrough in a Recently Infected HIV-1 Controller. EBioMedicine, 2017, 16, 141-149.	2.7	27
60	Geographic Differences in Temporal Incidence Trends of Hepatitis C Virus Infection Among People Who Inject Drugs: The InC3 Collaboration. Clinical Infectious Diseases, 2017, 64, 860-869.	2.9	61
61	Genetic basis for variation in plasma IL-18 levels in persons with chronic hepatitis C virus and human immunodeficiency virus-1 infections. Genes and Immunity, 2017, 18, 82-87.	2.2	6
62	Fine-mapping of genetic loci driving spontaneous clearance of hepatitis C virus infection. Scientific Reports, 2017, 7, 15843.	1.6	6
63	Phylogenetic analysis of full-length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC3 Study. Journal of Viral Hepatitis, 2017, 24, 43-52.	1.0	14
64	Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents. Journal of Viral Hepatitis, 2017, 24, 37-42.	1.0	11
65	Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance. JCI Insight, 2017, 2, .	2.3	129
66	HIV-antibody complexes enhance production of type I interferon by plasmacytoid dendritic cells. Journal of Clinical Investigation, 2017, 127, 4352-4364.	3.9	17
67	Continued Elevation of Interleukin-18 and Interferon- γ After Initiation of Antiretroviral Therapy and Clinical Failure in a Diverse Multicountry Human Immunodeficiency Virus Cohort. Open Forum Infectious Diseases, 2016, 3, ofw118.	0.4	19
68	TGF β 1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer. Cancer Discovery, 2016, 6, 1366-1381.	7.7	196
69	Favorable Socioeconomic Status and Recreational Polydrug Use Are Linked With Sexual Hepatitis C Virus Transmission Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men. Open Forum Infectious Diseases, 2016, 3, ofw137.	0.4	14
70	Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia. Journal of Infectious Diseases, 2016, 214, 1383-1389.	1.9	16
71	The effects of alcohol on spontaneous clearance of acute hepatitis C virus infection in females versus males. Drug and Alcohol Dependence, 2016, 169, 156-162.	1.6	10
72	Use of Hepatitis C Virus (HCV) Immunoglobulin G Antibody Avidity as a Biomarker to Estimate the Population-Level Incidence of HCV Infection. Journal of Infectious Diseases, 2016, 214, 344-352.	1.9	12

#	ARTICLE	IF	CITATIONS
73	The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design. <i>Gut</i> , 2016, 65, 112-123.	6.1	30
74	Interferon Lambda 4 Genotype Is Associated With Jaundice and Elevated Aminotransferase Levels During Acute Hepatitis C Virus Infection: Findings From the InC3 Collaborative. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw024.	0.4	1
75	Prophylactic Vaccines for the Hepatitis C Virus. , 2016, , 325-346.		1
76	Lessons from Nature: Understanding Immunity to HCV to Guide Vaccine Design. <i>PLoS Pathogens</i> , 2016, 12, e1005632.	2.1	13
77	IFNL3 genotype is associated with differential induction of IFNL3 in primary human hepatocytes. <i>Antiviral Therapy</i> , 2015, 20, 805-814.	0.6	4
78	Patterns of Hepatitis C Virus RNA Levels during Acute Infection: The InC3 Study. <i>PLoS ONE</i> , 2015, 10, e0122232.	1.1	41
79	Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection—the InC ³ Study. <i>Journal of Infectious Diseases</i> , 2015, 212, 1407-1419.	1.9	82
80	Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC ³ study. <i>Journal of Viral Hepatitis</i> , 2015, 22, 708-717.	1.0	13
81	Acute Hepatitis C Virus Infection Induces Consistent Changes in Circulating MicroRNAs That Are Associated with Nonlytic Hepatocyte Release. <i>Journal of Virology</i> , 2015, 89, 9454-9464.	1.5	19
82	Global control of hepatitis C virus. <i>Science</i> , 2015, 349, 790-791.	6.0	90
83	HIV and HCV Activate the Inflammasome in Monocytes and Macrophages via Endosomal Toll-Like Receptors without Induction of Type 1 Interferon. <i>PLoS Pathogens</i> , 2014, 10, e1004082.	2.1	159
84	Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses. <i>Hepatology</i> , 2014, 59, 2140-2151.	3.6	230
85	The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. <i>Hepatology</i> , 2014, 59, 109-120.	3.6	320
86	Not-so-innocent bystanders. <i>Nature</i> , 2014, 505, 492-493.	13.7	19
87	Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: The InC3 Study. <i>Journal of Clinical Virology</i> , 2014, 61, 430-434.	1.6	8
88	Admixture analysis of spontaneous hepatitis C virus clearance in individuals of African descent. <i>Genes and Immunity</i> , 2014, 15, 241-246.	2.2	9
89	Monocytes Activate Natural Killer Cells via Inflammasome-Induced Interleukin 18 in Response to Hepatitis C Virus Replication. <i>Gastroenterology</i> , 2014, 147, 209-220.e3.	0.6	81
90	Making Sense of HIV Innate Sensing. <i>Immunity</i> , 2013, 39, 998-1000.	6.6	2

#	ARTICLE	IF	CITATIONS
91	Hepatitis C Virus Vaccines Among People Who Inject Drugs. <i>Clinical Infectious Diseases</i> , 2013, 57, S46-S50.	2.9	31
92	Immunity and Hepatitis C: A Review. <i>Current HIV/AIDS Reports</i> , 2013, 10, 51-58.	1.1	25
93	Frequent Longitudinal Sampling of Hepatitis C Virus Infection in Injection Drug Users Reveals Intermittently Detectable Viremia and Reinfection. <i>Clinical Infectious Diseases</i> , 2013, 56, 405-413.	2.9	29
94	Cohort Profile: The International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3) Study. <i>International Journal of Epidemiology</i> , 2013, 42, 1649-1659.	0.9	48
95	Anti-inflammatory cytokines, pro-fibrogenic chemokines and persistence of acute HCV infection. <i>Journal of Viral Hepatitis</i> , 2013, 20, 404-413.	1.0	20
96	Evolution of CD8 ⁺ T Cell Responses after Acute PARV4 Infection. <i>Journal of Virology</i> , 2013, 87, 3087-3096.	1.5	16
97	Genome-Wide Association Study of Spontaneous Resolution of Hepatitis C Virus Infection: Data From Multiple Cohorts. <i>Annals of Internal Medicine</i> , 2013, 158, 235.	2.0	187
98	The More You Look, the More You Find: Effects of Hepatitis C Virus Testing Interval on Reinfection Incidence and Clearance and Implications for Future Vaccine Study Design. <i>Journal of Infectious Diseases</i> , 2012, 205, 1342-1350.	1.9	64
99	Immunogenicity and Cross-Reactivity of a Representative Ancestral Sequence in Hepatitis C Virus Infection. <i>Journal of Immunology</i> , 2012, 188, 5177-5188.	0.4	28
100	A Live-Attenuated <i>Listeria</i> Vaccine (ANZ-100) and a Live-Attenuated <i>Listeria</i> Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction. <i>Clinical Cancer Research</i> , 2012, 18, 858-868.	3.2	304
101	Computational Reconstruction of Bole1a, a Representative Synthetic Hepatitis C Virus Subtype 1a Genome. <i>Journal of Virology</i> , 2012, 86, 5915-5921.	1.5	21
102	Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 408-414.	4.6	186
103	Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. <i>Hepatology</i> , 2012, 55, 1684-1691.	3.6	63
104	Protective interleukin-28B genotype affects hepatitis C virus clearance, but does not contribute to HIV-1 control in a cohort of African-American elite controllers/suppressors. <i>Aids</i> , 2011, 25, 385-387.	1.0	20
105	High Plasma Interleukin-18 Levels Mark the Acute Phase of Hepatitis C Virus Infection. <i>Journal of Infectious Diseases</i> , 2011, 204, 1730-1740.	1.9	51
106	Hepatitis C virus evasion of adaptive immune responses: a model for viral persistence. <i>Immunologic Research</i> , 2010, 47, 216-227.	1.3	63
107	Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro. <i>Hepatology</i> , 2010, 52, 1581-1589.	3.6	100
108	Acceleration of Hepatitis C Virus Envelope Evolution in Humans Is Consistent with Progressive Humoral Immune Selection during the Transition from Acute to Chronic Infection. <i>Journal of Virology</i> , 2010, 84, 5067-5077.	1.5	70

#	ARTICLE	IF	CITATIONS
109	Spontaneous Control of Primary Hepatitis C Virus Infection and Immunity Against Persistent Reinfection. <i>Gastroenterology</i> , 2010, 138, 315-324.	0.6	316
110	Rare Birds in North America: Acute Hepatitis C Cohorts. <i>Gastroenterology</i> , 2009, 136, 26-31.	0.6	53
111	Selection Pressure From Neutralizing Antibodies Drives Sequence Evolution During Acute Infection With Hepatitis C Virus. <i>Gastroenterology</i> , 2009, 136, 2377-2386.	0.6	207
112	Monocyte derived dendritic cells retain their functional capacity in patients following infection with hepatitis C virus. <i>Journal of Viral Hepatitis</i> , 2008, 15, 219-228.	1.0	31
113	Human Immunodeficiency Virus-Related Microbial Translocation and Progression of Hepatitis C. <i>Gastroenterology</i> , 2008, 135, 226-233.	0.6	251
114	Hepatitis C Virus Immune Escape via Exploitation of a Hole in the T Cell Repertoire. <i>Journal of Immunology</i> , 2008, 181, 6435-6446.	0.4	61
115	High-Programmed Death-1 Levels on Hepatitis C Virus-Specific T Cells during Acute Infection Are Associated with Viral Persistence and Require Preservation of Cognate Antigen during Chronic Infection. <i>Journal of Immunology</i> , 2008, 181, 8215-8225.	0.4	114
116	CD4+T Cell-Dependent Reduction in Hepatitis C Virus-Specific Humoral Immune Responses after HIV Infection. <i>Journal of Infectious Diseases</i> , 2007, 195, 857-863.	1.9	33
117	Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. <i>Hepatology</i> , 2005, 42, 104-112.	3.6	211
118	Humoral Immune Response in Acute Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , 2005, 41, 667-675.	2.9	172
119	Cellular immune selection with hepatitis C virus persistence in humans. <i>Journal of Experimental Medicine</i> , 2005, 201, 1741-1752.	4.2	278
120	Prospective Evaluation of Community-Acquired Acute-Phase Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , 2005, 40, 951-958.	2.9	195
121	Protection against persistence of hepatitis C. <i>Lancet</i> , The, 2002, 359, 1478-1483.	6.3	426
122	Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. <i>Science</i> , 1994, 264, 716-719.	6.0	812
123	Direct identification of an endogenous peptide recognized by multiple HLA-A2.1-specific cytotoxic T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993, 90, 10275-10279.	3.3	122
124	Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. <i>Science</i> , 1992, 256, 1817-1820.	6.0	672
125	Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. <i>Science</i> , 1992, 255, 1261-1263.	6.0	1,189
126	Sequence analysis of peptides presented to the immune system by class I and class II MHC molecules. <i>The Protein Journal</i> , 1992, 11, 377-378.	1.1	0